Scarica l'app Stockscreener
2.26
0.68%
-0.0154
Dopo l'orario di chiusura:
2.26
Precedente Chiudi:
$2.2754
Aprire:
$2.29
Volume 24 ore:
12,395
Relative Volume:
0.28
Capitalizzazione di mercato:
$1.40M
Reddito:
-
Utile/perdita netta:
$-15.85M
Rapporto P/E:
-0.0945
EPS:
-23.9055
Flusso di cassa netto:
$-13.83M
1 W Prestazione:
-11.72%
1M Prestazione:
-27.80%
6M Prestazione:
-74.55%
1 anno Prestazione:
-84.93%
Intervallo 1D:
$2.15
$2.29
Intervallo di 1 settimana:
$2.15
$2.8183
Portata 52W:
$2.0573
$34.80
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Nome
Cns Pharmaceuticals Inc
Settore
Industria
Telefono
1-800-946-9185
Indirizzo
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
2.26 | 1.40M | 0 | -15.85M | -13.83M | -23.91 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-12-28 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-08-24 | Iniziato | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Borsa (CNSP) Ultime notizie
Profit Recap: Why is CNS Pharmaceuticals Inc stock going down2026 Macro Impact & Smart Swing Trading Alerts - baoquankhu1.vn
Exit Recap: Is CNS Pharmaceuticals Inc in a long term uptrend2026 Valuation Update & Daily Stock Momentum Reports - baoquankhu1.vn
CNSP PE Ratio & Valuation, Is CNSP Overvalued - Intellectia AI
CNS Pharmaceuticals | 10-K: Annual report - Moomoo
CNS Pharmaceuticals 10-K: Net loss $15.85M, Loss per share $35.75 - TradingView
CNS Pharmaceuticals (NASDAQ: CNSP) pivots to neurology and oncology amid going concern risk - Stock Titan
Pharma News: Will CNS Pharmaceuticals Inc outperform small cap indexesDip Buying & Verified Short-Term Trading Plans - baoquankhu1.vn
CNS Pharmaceuticals Inc expected to post a loss of $5.09 a shareEarnings Preview - TradingView
CNS PHARMACEUTICALS INC (CNSP) Fundamental Analysis & Valuation - ChartMill
Lunai Bioworks, Inc. (LNAI) Stock: No-Reset Convertible Deal Boosts CNS Drug Development Edge - parameter.io
Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications - PR Newswire
Is CNS Pharmaceuticals Inc in a long term uptrend2026 Earnings & Real-Time Market Sentiment Reports - baoquankhu1.vn
Stop Loss: Will CNS Pharmaceuticals Inc outperform small cap indexesPortfolio Performance Summary & Growth Oriented Trade Recommendations - baoquankhu1.vn
Aug Decliners: Is CNS Pharmaceuticals Inc forming a bullish divergence2026 Biggest Moves & Weekly Return Optimization Plans - baoquankhu1.vn
Movement Recap: Is CNS Pharmaceuticals Inc stock good for income investors2026 Movers & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
CNSP SEC FilingsCNS Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Death Cross: Is CNS Pharmaceuticals Inc forming a bullish divergence2026 Technical Overview & Free Community Consensus Stock Picks - baoquankhu1.vn
Will CNS Pharmaceuticals Inc stock go up in YEARWeekly Earnings Recap & Verified Swing Trading Watchlists - baoquankhu1.vn
CNS Pharmaceuticals shifts focus to neurology, oncology assets By Investing.com - Investing.com Nigeria
Quarterly Trades: Is CNS Pharmaceuticals Inc currently under institutional pressure2026 Trading Recap & Long-Term Capital Growth Strategies - baoquankhu1.vn
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - Business Wire
CNS Pharmaceuticals Unveils Strategic Pivot to Broader Oncology - The Globe and Mail
CNSP Implements New Strategy to Enhance Neurology and Oncology P - GuruFocus
CNS Pharmaceuticals Announces Strategic Shift to Neurology and Oncology Pipeline Expansion - citybuzz -
CNS Pharmaceuticals Launches Strategic Pivot Led by New Executive Team, Targeting High-Value Neurology and Oncology Assets for Investor Growth 123 - Minichart
CNS Pharmaceuticals (NASDAQ: CNSP) Launches New Growth Strategy Focused On Neurology and Oncology Pipeline Expansion - Digital Journal
CNS Pharma wipes glioblastoma pipeline clean in strategic pivot to fresh neurology, oncology targets - Fierce Biotech
CNS Pharmaceuticals shifts focus to neurology, oncology assets - Investing.com
CNS Pharmaceuticals launches strategic pivot, names new executive team and begins asset search - TradingView
CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline - ACCESS Newswire
New CNS Pharmaceuticals (NASDAQ: CNSP) team drives strategic pivot - Stock Titan
CNS Pharma shifts from single cancer focus to hunting new brain and tumor drugs - Stock Titan
Aug Final Week: Can CNS Pharmaceuticals Inc outperform under higher oil prices2026 Market Mood & Detailed Earnings Play Strategies - baoquankhu1.vn
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions - PR Newswire
CNS Pharmaceuticals (CNSP) Receives a Buy from Maxim Group - The Globe and Mail
Why is CNS Pharmaceuticals Inc stock going down2025 Price Momentum & Short-Term High Return Strategies - baoquankhu1.vn
CNSP Earnings History & Surprises | EPS & Revenue Results | CNS PHARMACEUTICALS INC (NASDAQ:CNSP) - ChartMill
9,500 RSUs awarded to CNS Pharmaceuticals (CNSP) CFO - Stock Titan
CNS Pharmaceuticals (CNSP) files insider Form 3 for Chief Financial Officer - Stock Titan
CNSP Financials: Income Statement, Balance Sheet & Cash Flow | CNS Pharmaceuticals - Stock Titan
CNS Pharmaceuticals (CNSP) CTO Eric Faulkner files initial insider Form 3 - Stock Titan
CNS Pharmaceuticals Appoints New Chief Medical Officer - The Globe and Mail
CNS Pharmaceuticals (NASDAQ: CNSP) Appoints Lynne Kelley as Chief Medical Officer - The Globe and Mail
CNS Pharmaceuticals names Lynne Kelley as chief medical officer By Investing.com - Investing.com Australia
CNS Pharmaceuticals (NASDAQ: CNSP) appoints new CMO Lynne Kelley - Stock Titan
CNS Pharmaceuticals (NASDAQ: CNSP) Appoints New Executive Leadership Team - Digital Journal
CNS Pharmaceuticals appoints Lynne Kelley as CMO - TipRanks
CNS Pharmaceuticals names Lynne Kelley as chief medical officer - Investing.com
CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team - ACCESS Newswire
Brain cancer drug developer hires veteran surgeon to lead studies - Stock Titan
Supernus Pharmaceuticals Record Revenues And New CNS Drugs Prompt Valuation Questions - Sahm
Cns Pharmaceuticals Inc Azioni (CNSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):